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Abstract.
Background:Alzheimer’s disease (AD) is diagnosed based on a clinical evaluation as well as analyses of classical biomarkers:
A42, total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF). Although the sensitivities and specificities
of the classical biomarkers are fairly good for detection of AD, there is still a need to develop novel biochemical markers for
early detection of AD.
Objective: We explored if integration of novel proteins with classical biomarkers in CSF can better discriminate AD from
non-AD subjects.
Methods: We applied ELISA, mass spectrometry, and multivariate modeling to investigate classical biomarkers and the
CSF proteome in subjects (n = 206) with 76 AD patients, 74 mild cognitive impairment (MCI) patients, 11 frontotemporal
dementia (FTD) patients, and 45 non-dementia controls. The MCI patients were followed for 4–9 years and 21 of these
converted to AD, whereas 53 remained stable.
Results: By combining classical CSF biomarkers with twelve novel markers, the area of the ROC curves (AUROCS) of
distinguishing AD and MCI/AD converters from non-AD were 93% and 96%, respectively. The FTDs and non-dementia
controls were identified versus all other groups with AUROCS of 96% and 87%, respectively.
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Conclusions: Integration of new and classical CSF biomarkers in a model-based approach can improve the identification of
AD, FTD, and non-dementia control subjects.
Keywords: Alzheimer’s disease, cerebrospinal fluid, ELISA, mass spectrometry, mild cognitive impairment, proteomics
INTRODUCTION
Currently, Alzheimer’s disease (AD) is diagnosed
based on a clinical evaluation with support from
imaging techniques as well as analyses of A42,
total tau (t-tau), and phosphorylated tau (p-tau) in
cerebrospinal fluid (CSF) [1]. The combination of
decreased A42, increased t-tau and p-tau is indica-
tive of AD with a sensitivity of 71–95% and a
specificity of 44–87% [2, 3]. Importantly, the sensi-
tivity can be even lower at prodromal disease stages,
i.e., in patients with an amnestic form of mild cogni-
tive impairment (MCI) who later will convert to AD
dementia [4]. Using logistic regression, studies have
evaluated the diagnostic accuracy of combining the
classical CSF markers with additional proteins such
as YKL-40, NFL, and neurogranin [5–8]. However,
such composite biomarker profiles for AD have so
far not resulted in any diagnostic improvements [8],
implying that there is still a need to identify addi-
tional biomarkers to further improve the diagnostic
accuracy of CSF analysis.
Here, we combined the classical AD CSF biomark-
ers with mass spectrometry (MS) based shotgun
proteomics data to assess if multivariate modelling
using sparse partial least squares discriminant analy-
sis (sPLS-DA) could improve the diagnostic accuracy
of recognizing AD from healthy controls and from
other conditions of cognitive dysfunction.
METHODS
Samples
This study includes CSF samples from 76 AD
patients, 74 mild cognitive impairment (MCI)
patients, 11 frontotemporal dementia (FTD) patients,
and 45 non-dementia controls. The MCI patients were
followed for 4–8 years at 6–12 months intervals and
eventually diagnosed with AD (MCI/AD convert-
ers) (n = 21) or remained at the MCI stage (stable
MCI) (n = 53). Samples were collected according to
the recommended consensus protocol for CSF col-
lection and biobanking [9]. All patients underwent
computed tomography or magnetic resonance imag-
ing scans, caregiver interviews, thorough cognitive
assessments, and in some cases regional glucose
uptake by positron emission tomography. The diag-
nosis of probable AD dementia was set according to
the National Institute of Neurological and Commu-
nicative Disorders and Stroke/Alzheimer’s Disease
and Related Disorders Association criteria [10] and
the Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Edition, criteria [11]. MCI was defined
according to the International Working Group of
MCI [12]. The control subjects were recruited by
advertising in the local newspaper and were consid-
ered cognitively unimpaired, based on their history
and a Mini-Mental State Examination (MMSE) test.
Approximately half of the controls consisted of
87–89-year-old men from the ULSAM cohort, indi-
viduals who have been followed since the early 1970 s
[13].
The Regional Ethical Review Board in Uppsala,
Sweden had approved the collection of CSF samples,
the conducted research (collection of the samples:
2005-244 and ¨O 48-2005; 2005-11-02 and 2006-01-
30 as well as the use of samples for the analyses:
2011/044; 2011-02-23). All participants provided
their written informed consent before any samples
were collected. The main clinical features of the
patients are summarized in Table 1 and Supplemen-
tary Table 1.
Sample handling and analysis
The detailed description of sample handling and
analysis is available in Supplementary Material 1.
Briefly, the CSF samples were collected via lumbar
puncture into polypropylene tubes. The concentra-
tions of A42, t-tau, and p-tau in CSF were measured
using sandwich ELISAs (INNOTEST, Fujirebio,
Ghent, Belgium) and procedures accredited by the
Swedish Board of Accreditation and Conformity
Assessment.
For MS analysis, the samples were first sub-
jected to multiaffinity immunodepletion to deplete
the seven most abundant proteins. The proteins in
the depleted CSF sample were digested to peptides
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Table 1
Main clinical features information of patients and controls. AD, Alzheimer’s disease; MCI, mild cognitive impairment;
FTD, frontotemporal dementia
AD MCI/AD Stable MCI FTD CONTROL
converter
Gender (F/M) 47/29 11/10 20/33 4/7 8/37
Age (Median[range]) 72 (54–88) 71 (59–79) 71 (44–81) 66 (50–75) 88 (74–89)
A42 ng/l (Median[range]) 405 (160–1160) 388 (234–645) 756 (320–1500) 720 (350–1180) 676 (337–1343)
t-tau ng/l (Median[range]) 617 (160–1720) 540 (329–1370) 244 (82–742) 281 (200–600) 414 (202–1121)
p-tau ng/l (Median[range]) 82 (28–220) 78 (35–184) 45 (22–97) 44 (24–59) 63 (29–122)
using a trypsin/Lys-C mixture, followed by nanoLC-
MS/MS analyses using a 7 T hybrid LTQ FT MS.
The samples were run in a random order and, in
addition, a pool of CSF was run after every eight
biological samples for the purpose of quality con-
trol. Identification and quantification of MS data were
performed using OpenMS [14]. Proteins identified
(q-value <0.05) with five or more significant pep-
tides (q-value <0.05) were included in downstream
analyses. The proteins with less than 20% missing
values in the QC samples and the biological sam-
ples and coefficients of variation (CV) <1 in the QC
samples were selected for modeling. The data was
transformed to log2 scale and normalized using cyclic
loess normalization on protein level [6]. The levels of
MS based proteins as well as A42, t-tau, p-tau, and
MMSE were adjusted for age and gender using linear
regression [7].
Identiﬁcation of AD using Aβ42, t-tau, and p-tau
at baseline
To assess diagnostic accuracy of AD based on
A42, t-tau, and p-tau at baseline, we performed clas-
sification of AD (A42 <530 (ng/L) and t-tau>350
(ng/L)) according to Hansson et al. [15]. For compar-
ison, the results of additional cutoffs, as suggested by
Hansson et al. [15], were also included.
Multivariate modelling to diagnose AD using
Aβ42, t-tau, and p-tau at baseline
We evaluated if PLS-DA could improve the accu-
racy of diagnosing AD versus non-AD subjects
(MCIs, FTDs, and non-dementia controls) by tak-
ing combinatorial effects of A42, t-tau, and p-tau
into account. A linear model using PLS-DA [20]
was trained using the three components for predic-
tion. Importantly, for training, MCI/AD converters
and MCI/non-AD converters were regarded as a sin-
gle group, “MCI”. Therefore, the model was not
provided with information on whether the MCI
patients were AD converters or not. A leave-one-
out cross-validation was performed to evaluate the
accuracy by calculating an area of the ROC curve
(AUROC) for AD versus non-AD subjects (stable
MCI, FTD, and controls), MCI/AD converters versus
non-AD subjects (FTD, stable MCI, and controls),
FTD versus non-FTD subjects (AD, MCI/AD con-
verters, stable MCI, and controls) and controls versus
all other groups (cognitively declined patients).
Integrative multivariate statistical analysis
Using sparse PLS-DA (sPLS-DA), we evaluated if
a combination of A42, t-tau, and p-tau levels with
levels of proteins evaluated by MS could improve the
diagnostic performance. The training and evaluation
of the model, was the same as for the PLS-DA model
described above. The variable importance (VIP) of
the four most important variables (proteins) for each
of the four components used for the diagnostic pre-
diction were automatically selected and extracted
from the model using mixOmics [16]. The AUROCs
were compared between the models using DeLong
test.
Univariate statistical analysis
Nonparametric tests (Kruskal-Wallis, KW) were
performed to evaluate group-wise differences of
A42, t-tau, p-tau, and proteins found in the sPLS-DA
analysis. For statistically significant (p < 0.05) results
of the KW test, pairwise post hoc comparisons were
performed using Mann-Whitney U Test. A result of
p < 0.05 was considered statistically significant.
Correlation analysis
The Spearman’s rank-order correlation was per-
formed to evaluate association between A42, t-tau,
p-tau and proteins found in the sPLS-DA analysis.
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Fig. 1. Alzheimer’s disease classification criteria, as reported by Hansson et al. [15]. The dashed lines represent cutoff levels based on A42
<530 (ng/L), t-tau>350 (ng/L), and p-tau> = 60 (ng/L).
A result of p < 0.05 was considered statistically
significant.
RESULTS
The clinical features of the 206 subjects are sum-
marized in Table 1 and Supplementary Table 1. The
76 AD patients were 54–88 years old and 62% were
women. The 74 MCI patients were 59–79 years old
and 52% were women. During the 4–8 years follow-
up period, 21 of the MCI patients were diagnosed with
AD. The eleven FTD patients were 50–75 years old
and 57% were women. The non-neurological control
subjects were 74–89 years old and 18% were women.
Upon KW tests there was a significant age difference
(p < 0.001), as well as of age and gender adjusted
MMSE level (p < 0.001) between the groups. The
pairwise post hoc testing showed that controls were
significantly older than AD, MCI/AD converters, and
stable MCI and FTDs (p < 0.001). The MMSE scores
were significantly lower for AD (p < 0.01) and sta-
ble MCI (p < 0.05) compared to controls. Moreover,
the MMSE scores were significantly lower in AD
(p < 0.001) compared to both MCI/AD converters and
stable MCI.
Identiﬁcation of AD using Aβ42, t-tau, and p-tau
at baseline
To assess diagnostic accuracy of A42, t-tau, and
p-tau at baseline, we performed classification of AD,
FTD, MCI/AD converters, and non-dementia con-
trols according to Hansson et al. [15]. The cut off
levels of A42 <530 (ng/L) and t-tau>350 (ng/L)
resulted in an accuracy for identification of AD of
72% (55 out of 76) and incipient AD of 71% (15
out 21). Using this cutoff none of the FTD subjects
were classified as AD, but 31% (14 out of 45) of the
non-dementia controls were falsely classified as AD.
The results using alternative cutoffs, as suggested by
Hansson et al. [15], are found in Fig. 1 and Supple-
mentary Table 3. However, the regular cut off levels
of A42 <530 (ng/L) and t-tau>350 (ng/L) showed
the best diagnostic performance.
Multivariate modelling to diagnose AD using
Aβ42, t-tau, and p-tau at baseline
We evaluated if PLS-DA modelling could improve
the accuracy of diagnosing AD and MCI/AD con-
verters whilst also correctly classifying FTD and
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Fig. 2. Comparison of AUROCs between the classical model (ELISA measurements of A42, t-tau, p-tau) and the integrative model (ELISA
measurements of A42, t-tau, p-tau in combination with MS-based measurements of 12 proteins). AD, Alzheimer’s disease; MCI, mild
cognitive impairment; FTD, frontotemporal dementia.
non-dementia controls (Fig. 2). This resulted in
an AUROC of 92% for discriminating AD versus
non-AD subjects and 96% for detecting MCI/AD
converters (p < 0.01). The AUROC for distinguishing
FTD versus all other groups was 57% (not statistically
significant). The AUROC for recognition of con-
trols versus cognitively declined subjects was 75%
(p < 0.01).
Integrative multivariate modeling to identify
incipient AD
Next, we evaluated if a combination of A42, t-tau,
and p-tau levels with MS based protein measurements
could improve the diagnostic accuracy using sPLS-
DA. Label free shotgun MS was used to analyze the
proteome in all CSF samples. A total of 672 proteins
were identified and quantified. After applying sample
coverage and CV cutoffs, 78 proteins remained for
downstream analyses.
Using sPLS-DA the AUROC for identifying AD
versus non-AD was 93% and the recognition of
incipient AD (MCI/AD converters) was 96% versus
non-AD. The AUROC for distinguishing FTD versus
non-FTD increased to 96% (p < 0.01). As for recog-
nition of controls versus all other groups, AUROC
increased to 87% (p < 0.01) (Fig. 2). Comparing the
AUROC for the model on the classical biomarkers
to the integrated model, the improvements on dis-
tinguishing controls versus others and FTD versus
others were statistically significant (p < 0.005).
Disease-associated proteins
Using sPLS-DA we evaluated the different pro-
teins relative contribution to the model predictions
(Fig. 3). They were in decreasing order: A42, t-
tau, p-tau, cadherin-2, neurosecretory protein VGF,
afamin, plasma protease C1 inhibitor, inter-alpha-
trypsin inhibitor heavy chain H4, apolipoprotein A-I,
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Fig. 3. Variable importance extracted from the sPLS-DA model
trained on a model of proteins (MS) and A42, t-tau, and p-tau.
The model selected the proteins with the most influence on the
responses resulting in a total of 15 unique variables including
A42, t-tau, and p-tau. A42 (VIP = 6.80), t-tau (VIP = 4.29), p-
tau (VIP = 3.84), cadherin-2 (VIP = 3.68, Uniprot AC: P19022,
Uniprot ID: CADH2), neurosecretory protein VGF (VIP = 3.49,
Uniprot AC: O15240, Uniprot ID: VGF), afamin (VIP = 2.41,
Uniprot AC: P43652, Uniprot ID: AFAM), plasma protease C1
inhibitor (VIP = 2.38, Uniprot AC: P05155, Uniprot ID: IC1),
inter-alpha-trypsin inhibitor heavy chain H4 (VIP = 2.01, Uniprot
AC: Q14624, Uniprot ID: ITIH4), apolipoprotein A-I (VIP = 1.75,
Uniprot AC: P02647, Uniprot ID: APOA1), secretogranin-2
(VIP = 1.47, Uniprot AC: P13521, Uniprot ID: SCG2), beta-
Ala-His dipeptidase (VIP = 1.15, Uniprot AC: Q96KN2, Uniprot
ID: CNDP1), alpha-1B-glycoprotein (VIP = 0.58, Uniprot AC:
P04217, Uniprot ID: A1BG), chitinase-3-like protein 1 (VIP = 0.5,
Uniprot AC: P36222, Uniprot ID: CH3L1, also known as YKL-40),
cystatin-C (VIP = 0.43, Uniprot AC: P01034, Uniprot ID: CYTC)
and SPARC (VIP = 0.15, Uniprot AC: P09486, Uniprot ID: SPRC).
secretogranin-2, beta-Ala-His dipeptidase, alpha-1B-
glycoprotein, chitinase-3-like protein 1 (also known
as YKL-40), cystatin-C and SPARC.
Univariate statistical testing on the selected
proteins
The results of KW and Mann-Whitney tests on age
and gender adjusted CSF protein levels are illustrated
in Fig. 4. The CSF levels of A42 were lower for
AD and MCI/AD converters compared to stable MCI,
FTD, and controls. The levels of t-tau and p-tau were
higher in AD and MCI/AD converters compared to
stable MCI, FTD and controls, but lower in stable
MCI compared to controls. The levels of cadherin-
2 were higher in FTD compared to controls, AD,
MCI/AD converters, and stable MCI. The levels of
neurosecretory protein VGF were lower in AD, stable
MCI and FTD compared to controls. The levels of
afamin were higher in AD, stable MCI and FTD com-
pared to controls. The levels of plasma protease C1
inhibitor were higher in FTD compared to controls,
AD, MCI/AD converters, and stable MCI. The lev-
els of apolipoprotein A-I were higher in AD, stable
MCI, and FTD compared to controls. The levels of
beta-Ala-His dipeptidase were lower in AD, stable
MCI, and FTD compared to controls. Chitinase-3-
like protein 1 (YKL-40) was the only protein with
higher levels only in AD and MCI/AD converters
compared to controls. The levels of Cystatin-C were
lower in FTD compared to controls. Finally, the levels
of SPARC were higher in AD, MCI/AD converters,
stable MCI, and FTD compared to controls (Supple-
mentary Table 4).
Correlations between CSF biomarkers
Figure 5 shows the correlation matrix between
A42, t-tau, and p-tau and the twelve MS-based
proteins. A42 showed a statistically significant cor-
relation to t-tau, p-tau, VGF, and YKL-40. Total-tau
showed a statistically significant correlation to all
the analyzed biomarkers except plasma protease C1
inhibitor and cystatin-C. Levels of p-tau were also
found to be correlated to the levels of all the mark-
ers, except for plasma protease C1 inhibitor. In
general, the levels of most proteins showed an inter-
correlation, with the exception of plasma protease
C1 inhibitor, YKL-40, and SPARC that were found
to correlate less frequently to other proteins.
DISCUSSION
The use of CSF biomarkers to support the diagno-
sis of AD has become gradually more accepted and is
today broadly used at memory disorder units in many
countries. Although the sensitivities and specificities
of the ELISA-based measures of A42, t-tau, and p-
tau are fairly good there is still a need to develop novel
biochemical markers. In this study, we assessed the
CSF levels of the classical AD biomarkers but also
applied mass spectrometry to identify additional CSF
proteins that were evaluated individually and in com-
bination with the ELISA-based markers. In addition
to AD and MCI patients, FTD patients and healthy
controls were represented among the 206 subjects
included.
By only evaluating the combination of CSF t-tau
and A42 we found, in agreement with others [8, 15],
that AD and MCI/AD converters could be recognized
with an acceptable accuracy (72% and 71% cor-
rect classification), although these markers showed
a tendency to diagnose non-dementia controls as AD
subjects. Allowing for combinatorial effects of A42,
P.E. Khoonsari et al. / Improved Differential Diagnosis of Alzheimer’s Disease 645
Fig. 4. Boxplots of CSF levels of the analyzed proteins. The levels were compared between the different groups with nonparametric statistical
testing. A: A42, B: t-tau, C: p-tau, D: cadherin-2 (Uniprot AC: P19022, Uniprot ID: CADH2), E: neurosecretory protein VGF (Uniprot AC:
O15240, Uniprot ID: VGF), F: afamin (Uniprot AC: P43652, Uniprot ID: AFAM), G: plasma protease C1 inhibitor (Uniprot AC: P05155,
Uniprot ID: IC1), H: apolipoprotein A-I (Uniprot AC: P02647, Uniprot ID: APOA1), I: beta-Ala-His dipeptidase (Uniprot AC: Q96KN2,
Uniprot ID: CNDP1), J: chitinase-3-like protein 1(Uniprot AC: P36222, Uniprot ID: CH3L1, also known as YKL-40), K: cystatin-C (Uniprot
AC: P01034, Uniprot ID: CYTC) and L: SPARC (Uniprot AC: P09486, Uniprot ID: SPRC). AD, Alzheimer’s disease; MCI, mild cognitive
impairment; FTD, frontotemporal dementia. p-value: ∗∗∗∗0–0.0001, ∗∗∗0.0001–0.001, ∗∗0.001–0.01, ∗0.01–0.05.
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Fig. 5. Rank based correlations of the selected proteins. A42, t-tau, p-tau, cadherin-2 (Uniprot AC: P19022, Uniprot ID: CADH2), neu-
rosecretory protein VGF (Uniprot AC: O15240, Uniprot ID: VGF), afamin (Uniprot AC: P43652, Uniprot ID: AFAM), plasma protease C1
inhibitor (Uniprot AC: P05155, Uniprot ID: IC1), inter-alpha-trypsin inhibitor heavy chain H4 (Uniprot AC: Q14624, Uniprot ID: ITIH4),
apolipoprotein A-I (Uniprot AC: P02647, Uniprot ID: APOA1), secretogranin-2 (Uniprot AC: P13521, Uniprot ID: SCG2), beta-Ala-His
dipeptidase (Uniprot AC: Q96KN2, Uniprot ID: CNDP1), alpha-1B-glycoprotein (Uniprot AC: P04217, Uniprot ID: A1BG), chitinase-3-like
protein 1(Uniprot AC: P36222, Uniprot ID: CH3L1, also known as YKL-40), cystatin-C (Uniprot AC: P01034, Uniprot ID: CYTC) and
SPARC (Uniprot AC: P09486, Uniprot ID: SPRC). p-value: ∗∗∗∗0–0.0001, ∗∗∗0.0001–0.001, ∗∗0.001–0.01, ∗0.01–0.05.
t-tau, p-tau, using PLS-DA, improved the accuracy of
identifying AD and MCI/AD converters, although the
accuracies for recognizing FTDs and non-dementia
controls remained low. This means that these mark-
ers play a very limited role as a diagnostic test for
objectively diagnosing AD, but they serve a purpose
when AD is suspected and other diseases have been
excluded. Therefore, complementary information is
necessary for development of a test based diagnostic
system.
When combining the classical biomarkers with
MS-based markers the diagnostic accuracy of distin-
guishing AD (including MCI/AD converters) from
patients with other cognitive conditions and healthy
controls could be improved just marginally (AUROC
for AD: 93% compared to 92%; for MCI/AD con-
verters 96% compared to 93%). These findings are
in line with the work by Hampel et al. [8], which
demonstrated that a combination of additional pro-
teins (NFL, neurogranin, and YKL-40; as measured
by ELISA) could improve the identification of AD
from controls (AUROC of 86% compared to 84%)
and of AD from FTD (AUROC of 82% compared
to 80%). However, their combined additional pro-
teins could not result in an accurate identification
of FTD versus healthy controls (maximum AUROC
of 78%) and more importantly healthy controls from
MCI subjects (maximum AUROC of 62%).
In our study, the combination of ELISA- and MS-
based data substantially improved the identification
of FTD as compared to the ELISA-based data alone
(AUROC of 96% compared to 57%, versus all other
groups). In addition, the non-dementia controls could
also be recognized with a much improved accuracy as
compared to the ELISA-based data alone (AUROC
of 87% compared to 75%, versus all other groups).
P.E. Khoonsari et al. / Improved Differential Diagnosis of Alzheimer’s Disease 647
Multivariate modeling
The modelling approach of combining CSF A42,
t-tau, and p-tau with MS-based markers has several
implications. Importantly, the information regarding
which MCI subjects that subsequently converted to
AD was not provided to the model at the training
stage. By excluding this information, we maintained
a high level of stringency and avoided bias for early
diagnosis of AD by instead letting the model extract
early AD pattern from the data. Therefore, the esti-
mated accuracies for AD and MCI/AD converters
should rather be viewed as underestimations. Also,
despite that our model increased the risk of misclas-
sification (since the classification was done for each
group against all other groups instead of in a pair-wise
fashion) it could improve the diagnostic accuracy for
AD and FTD as well as more accurately recognize
non-dementia controls.
Disease-associated proteins
To our knowledge this report represents the largest
MS based proteomics study on AD CSF published
to date. We undertook a very rigorous experimental
approach, where we created a CSF QC pool, which
was divided into subsamples that were treated like all
other samples, i.e. by depletion, digestion and mea-
surement. This approach allowed us to set an extra
stringent cutoff level for the CV of proteins that were
included in the final analyses. In addition, we deliber-
ately used a very conservative cutoff for the inclusion
of proteins (at least five unique peptides, as compared
to the standard procedure of including only two [17]).
This conservative approach necessarily leads to an
underestimation of the number of proteins that could
have been included in the analyses, at the benefit of
only including high-abundant proteins displaying low
technical variation.
Importantly, the three traditional markers (A42,
t-tau, and p-tau) were identified as the top three
variables. In addition, the automatic variable selec-
tion resulted in the identification of twelve others
proteins that were useful for the discrimination of
AD, MCI/AD converters, stable MCI, FTD, and non-
dementia controls. Nine of these proteins were found
to be altered across the groups, according to the KW
test.
Additional AD markers
The VGF protein was ranked high in the list,
indicating its value of being included in a panel of
biomarkers for AD differential diagnosis. In agree-
ment with previous reports we found decreased levels
of VGF in AD compared to non-dementia controls
[18–21] as well as in FTD compared to controls [18,
21]. Moreover, we found that the VGF levels were
increased in stable MCI compared to AD, which is
also in agreement with recent findings [21]. However,
we did not find any difference between MCI/AD con-
verters and stable MCI, contrary to what was recently
reported [21].
In agreement with other studies [22–27], we
found increased CSF levels of YKL-40 in AD and
MCI/AD converters compared to non-dementia con-
trols. Increased levels of YKL-40 in FTD compared
to both controls [5] and AD [8] have been previously
reported. However, in the current study we did not
find any increase in FTD compared to non-dementia
controls (p = 0.07), which may be due to the limited
number of FTD cases included (n = 11). The value
of adding YKL-40 in combination with traditional
markers is likely to be associated with distinguishing
between dementia and non-dementia controls and to
some extent between AD and FTD.
Markers of neurodegeneration and cognitive
decline
The increase in afamin CSF levels in AD, sta-
ble MCI, and FTD compared to controls, which
correlated strongly to those of apolipoprotein A-I
(correlation coefficient of 0.73), have, to our knowl-
edge, not been previously demonstrated. Moreover,
the CSF levels of beta-Ala-His dipeptidase were
found to be lower in AD, FTD and stable MCI com-
pared to controls.
We found increased CSF levels of apolipoprotein
A-I in AD, stable MCI, and FTD compared to non-
dementia controls. The results with respect to AD
corroborate those of a previous study [28], whereas
other studies have failed to replicate those results [29,
30].
SPARC was also found at lower levels in all the
patient groups compared to control subjects, indicat-
ing its usefulness as a more general biomarker for
cognitive decline. Increased CSF levels of the closely
related SPARC like 1 protein have been previously
reported in AD and MCI compared to controls [31].
Thus, these four proteins seem to have a more gen-
eral role in neurodegeneration [28, 32–34] and they
probably could serve as biomarkers only when used
in combination with other markers.
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FTD markers
The CSF levels of cadherin-2 were found to be
specifically increased in FTD compared to all other
groups. The protein was ranked just after the tradi-
tional markers, meaning that it had a high value to
discriminate the different groups from each other.
We found plasma protease C1 inhibitor to be higher
in FTD compared to controls, which contradicts the
hypothesis that this protein is AD specific, as previ-
ously suggested [35].
For cystatin-C we were not able to detect the previ-
ously reported decrease in AD compared to controls
[36]. However, the levels were decreased in FTD
compared to all other groups, which is in accor-
dance with a previous study [37]. Cystatin-C has
been implicated as a potential diagnostic marker in
both AD, other neurodegenerative diseases and cog-
nitive decline [38, 39]. The CSF levels of cystatin-C
showed significant correlation with plasma protease
C1 inhibitor and cadherin-2 but with low magnitude,
suggesting that these proteins may be complementary
to each other and that their value as biomarkers there-
fore may depend on covariations with other proteins.
Regarding the interpretations of single proteins,
it is of importance to emphasize that several mark-
ers were found to correlate with each other, but the
magnitudes of the correlations were in general small
indicating that the markers are complementary to
each other and thus could be used in a combinatorial
setting. In line with this, the value from the remaining
three proteins were most likely also based on covaria-
tions with other proteins, making it harder to interpret
their respective values. Among these, inter-alpha-
trypsin inhibitor heavy chain H4, secretogranin-2 and
alpha-1B-glycoprotein have previously all been asso-
ciated with AD [36, 40, 41].
Integrated diagnostics in the clinic
The molecular events in neurological diseases are
complex, emphasizing that no single marker alone
can reflect the full pathology. Using a combina-
tion of A42, t-tau, and p-tau in CSF is efficient
for diagnosing AD and MCI/AD converters, but
mainly serves a purpose when other diseases have
been excluded. Recent advances in modern tech-
nologies have enabled comprehensive measurements
of patients suffering from neurological diseases
at different molecular levels [42]. Considering the
complexity of pathological events, integrating infor-
mation from multiple sources can therefore result in
a more refined tool for diagnostic and prognostic
purposes. An example of this is that the incorpora-
tion of APOE4 allele information to spectrochemical
analysis of can improve the differential diagnosis in
AD [43].
We have here demonstrated that adding a limited
number of CSF protein measurements in a model-
based manner can improve the differential diagnosis.
In line with this, we have recently demonstrated
that integration of CSF protein, metabolite, and MRI
measurements can improve differential diagnosis in
multiple sclerosis [44]. Integrative diagnostics holds
great potential in future diagnostic assessments, yet
the challenge is to identify a limited number of
markers that holds complementary information and
that preferably can be acquired in a clinical setting.
The traditional CSF markers (A42, t-tau, and p-tau)
play a central role in AD, but by adding proteins to
the model we have here demonstrated that this can
improve the differential diagnosis to FTD and recog-
nition of non-dementia controls. By inclusion of more
disease specific markers, this could be developed into
a more general and multipurpose diagnostic test for
neurological diseases that could be used in the clinic.
However, translating this into routine healthcare will
necessitate rigorous validation process and general
acceptance of such a combinatorial test system. This
requires more integrative studies to demonstrate and
confirm the potential of combinatorial biomarker
panels.
Limitations of the study
There are a number of limitations to the present
study. Firstly, the values of the MS-based proteins
represent normalized relative intensities and are thus
not representing their respective absolute concen-
trations. In contrast A42, t-tau, and p-tau were
measured by a sandwich ELISA. Secondly, the sam-
ple size of our cohort was small (especially the FTD
group) and all subjects were recruited at one single
center. The findings have not been validated in an
independent cohort. Therefore, the results might not
be applicable to the general population. In addition,
there was an age and gender bias, as our non-dementia
controls were mostly men and older than the cogni-
tively declined subjects. We controlled for age and
gender in our statistical analyses, but an impact from
these factors cannot be entirely ruled out. Lastly,
the model fitting and calculation of AUROC were
based on the latest known health status of the sub-
jects. Therefore, classification of controls as, e.g.,
AD or MCI/AD converters can be both due to true
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miss-classification or the subjects having presymp-
tomatic AD.
Conclusions
By combining the ELISA-based classical AD CSF
biomarkers with a set of protein markers identified
by MS, a marginal improvement of the diagnostic
accuracy of AD and incipient AD at the MCI stage
could be achieved. Moreover, FTD patients could be
distinguished from non-FTD and non-dementia con-
trols could be distinguished from cognitively declined
subjects with significantly enhanced precision. Our
findings thus suggest that incorporating new CSF
biomarkers into the currently adopted diagnostic test
can further improve the differential diagnosis of AD
and concludes that integrative diagnostics holds great
potential in future diagnostic assessments. Further
studies are needed to investigate the generalizability
of our results.
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